AVEO prices offering to raise $50m for commercialization of tivozanib
This article was originally published in Scrip
AVEO Pharmaceuticals began selling 6.7 million shares of common stock at $7.50 per share on 17 January - at a discount to the stock's previous closing price of $8.12 - to raise $50 million in gross proceeds for working capital, including funds for the commercialization of tivozanib in the treatment of advanced renal cell carcinoma (RCC).
You may also be interested in...
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.